Evaluation of the efficacy and safety of injectable glycosaminoglycan-peptide complex (GPC) in patients with osteoarthritis: a multicenter observational study GLADIOLUS (GPC in the treatment of osteoarthritis: a follow-up study of pain relief and local symptom reduction)
Оценка эффективности и безопасности инъекционного гликозаминогликан-пептидного комплекса (ГПК) у пациентов с остеоартритом: многоцентровое наблюдательное исследование GLADIOLUS (ГПК в лечении остеоартрита: последующее наблюдение для оценки уменьшения боли и локальных симптомов)
2020-05-30
SCID: 54.1/va4cjqsn
Discuss with AI
glycosaminoglycan-peptide complexinjectable extended-release symptomatic agentmulticenter observational studyosteoarthritispain relief
Figures from the paper
Abstract (AI)
Glycosaminoglycan-peptide complex (GPC) is a popular injectable extended-release symptomatic agent (ERSA) in Russia for the treatment of osteoarthritis (OA). To date, no large-scale studies of GPC used in real clinical practice have been conducted in our country.Objective: to evaluate the efficacy and safety of GPC in the treatment of OA in real clinical practice.Patients and methods. A multicenter observational non-interventional study was performed to evaluate the efficacy of GPC (Rumalon® , a cycle of intramuscular injections thrice weekly; a total of 25 injections). A study group consisted of 2,955 patients (75.4% female) aged 61.4±11.8 years) with knee and hip OA, and generalized OA (GOA) with the previous inefficacy of oral ERSAs, moderate/severe pain, and the need for regular use of nonsteroidal anti-inflammatory drugs (NSAIDs). 414 (14%) patients received a GPC and diacerein combination 100 mg/day. The investigators assessed the dynamics of pain during movement and at rest, functional disorders (on a numeric rating scale (NRS) of 0–10), as well as the need for NSAIDs at 12 weeks after starting the GPC cycle.Results and discussion. 98.5% of the patients completed their GPC treatment cycle. The therapy decreased the intensity of pain at rest from 4 [3; 5] to 1 [0; 2] and during movement from 6 [5; 7] to 2 [1; 3] and reduced the severity of functional disorders from 5 [4; 6] to 1 [0; 3]. The number of patients with a good response to therapy (a≥50% decrease in symptom severity) for pain at rest and during movement was 55.6 and 53.5%, respectively; and for functional disorders was 50.8%. 68.1% of patients stopped taking NSAIDs. The GPC and diacerein combination was more effective than GPC monotherapy: the number of patients with a ≥50% decrease in movement pain was 62.8 and 54.3%, respectively (p <0.001). GPC was well tolerated. During treatment, there were skin allergic reactions (0.3%), moderate injection-site pain (0.37%), and adverse reactions (ARs) related to the gastrointestinal tract (8%) and cardiovascular system (6%) (which were likely to be caused by NSAIDs). There were no serious ARs that were life-threatening and required hospitalization.Conclusion. GPC allows successful control of the main symptoms of knee and hip OA and GOA, by reducing pain, and those of functional disorders, and the need for NSAIDs. The GPC and diacerein combination is more effective than GPC monotherapy. GPC therapy is well tolerated and very rarely causes ARs.
Key Findings
1
At least 50% symptom improvement occurred in 55.6% of patients for resting pain, 53.5% for movement pain, and 50.8% for functional impairment.
2
GPC reduced median pain at rest from 4 to 1, movement pain from 6 to 2, and functional impairment from 5 to 1 at 12 weeks.
3
GPC treatment enabled 68.1% of patients to discontinue NSAIDs; adding diacerein improved movement-pain response compared with GPC monotherapy (62.8% versus 54.3%, p<0.001).
4
GPC was generally well tolerated, with infrequent skin allergic reactions (0.3%) and moderate injection-site pain (0.37%).
5
In a multicenter real-world study of 2,955 patients with osteoarthritis, 98.5% completed the 25-injection intramuscular GPC treatment cycle.
Research Object
Injectable glycosaminoglycan-peptide complex (GPC) treatment in patients with knee, hip, and generalized osteoarthritis
Research Subject
The efficacy, safety, pain relief, functional improvement, and reduction in NSAID use associated with GPC therapy in real-world osteoarthritis care
Publication Details
Publication Date
2020-05-30
Journal
Publisher
ISSN
Cited by
4
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai3
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 20172018
An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)2019
Glycosaminoglycan-peptide complex in the treatment of knee and hip osteoarthritis: from the past to the future2020
Cited by3
Efficacy of combined use of glycosaminoglycan peptide complex for intramuscular administration and oral diacerein in osteoarthritis: evaluation according to an observational multicenter clinical trial2021
Glycosaminoglycan-peptide complex: data on the mechanism of action and efficacy in osteoarthritis2023
The efficacy and safety of glycosaminoglycan-peptide complex in patients with knee osteoarthritis and comorbidity: a multicenter prospective study2021